Hui‐Yi Lin

Moffitt Cancer Center

Papers

1

Total Citations

41

H-Index

1

About

Hui‐Yi Lin is a urologic oncologist whose research centers on improving surgical outcomes for upper tract urothelial carcinoma (UTUC), with a particular focus on the role of lymph node dissection. Her landmark work includes a prospective clinical trial evaluating the feasibility and safety of modified retroperitoneal lymph node dissection (RPLND) at the time of nephroureterectomy. This study, cited 41 times, was the first clinical trial to prospectively demonstrate that RPLND can be performed safely during nephroureterectomy, addressing a critical gap in knowledge about the potential oncological benefits of this procedure. By providing evidence that such an approach is feasible without increasing complications, Lin's work has helped refine surgical standards for UTUC, offering patients a more comprehensive treatment option. Her contributions are especially impactful given the historically limited data on lymph node management in upper tract tumors. Lin's research continues to influence urologic oncology, guiding surgeons toward more aggressive yet safe lymph node dissection strategies that may improve staging accuracy and long-term outcomes.

Research Focus

Key Achievements

1
H-Index
1
Papers
41
Total Citations
41
Avg Citations/Paper
🏆 Most Cited Paper
Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma
41 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Moffitt Cancer Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago